한글목차

혈관 운동 증상의 동향 및 예측

세계 혈관 운동 증상 시장은 2024년부터 2030년까지 연평균 5.8%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 좌식 생활 습관, 유전, 호르몬 변동, 식습관 장애로 인한 혈관 운동 증상의 빈도 증가, 연구 개발 자금을 지원하는 기업 및 잠재적인 임상시험에 참여하는 기업 증가입니다. 병원, 클리닉 및 전문센터 시장에서의 기회로 인해 혈관 운동 증상에 대한 세계 시장의 미래는 매우 유망합니다.

혈관운동증상 시장 인사이트

Lucintel의 예측에 따르면, 혈관 운동 증상에 대한 효과적인 치료를 위해 병용 요법이 예측 기간 동안 더 큰 부문을 차지할 것으로 보입니다.

이 시장에서는 혈관 운동 증상 치료에 대한 전문 지식이 풍부한 전문센터가 계속해서 큰 부분을 차지할 것으로 보입니다.

북미는 갱년기 장애의 높은 유병률로 인해 예측 기간 동안 가장 규모가 큰 지역으로 남을 것입니다.

자주 묻는 질문

Q1. 시장 성장 전망은?

A1. 세계 혈관 운동 증상 시장은 2024년부터 2030년까지 연평균 5.8%의 성장률을 보일 것으로 예상됩니다.

Q2. 시장 성장에 영향을 미치는 주요 촉진요인은 무엇인가?

A2. 이 시장의 주요 촉진요인은 좌식 생활 습관, 유전, 호르몬 변동, 식습관 장애로 인한 혈관 운동 증상의 빈도 증가, 연구 개발 자금을 제공하는 기업 및 잠재적인 임상시험에 참여하는 기업 증가입니다.

Q3. 시장의 주요 부문은?

A3. 혈관 운동 증상 시장의 미래는 병원 및 클리닉과 전문센터 시장에서의 기회로 인해 유망합니다.

Q4. 시장의 주요 기업은?

A4. 혈관 운동 증상 주요 기업은 다음과 같습니다.

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter And Gamble
• Therapeuticsmd
• Emcure Pharmaceuticals
• Eli Lily And Company
• Novartis
• Novo Nordisk
• Pfizer

Q5. 향후 가장 큰 시장 부문은?

A5.Lucintel은 예측 기간 동안 혈관 운동 증상에 대한 효과적인 치료를 위해 병용 요법이 더 큰 부문을 차지할 것으로 예상하고 있습니다.

Q6. 향후 5년간 가장 큰 시장으로 성장할 것으로 예상되는 지역은?

A6. 북미의 폐경기 유병률이 높기 때문에 예측 기간 동안 북미가 가장 규모가 큰 지역으로 남을 것입니다.

Q7. 보고서 커스터마이징이 가능한가?

A7. 네. Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 혈관 운동 증상 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 혈관 운동 증상 시장 동향(2018-2023)과 예측(2024-2030)
• 세계의 혈관 운동 증상 시장 : 치료법별
  • 에스트로겐
  • 프로게스테론
  • 혼합
  • OTC 호르몬
  • 항우울제
  • 기타
• 세계의 혈관 운동 증상 시장 : 유통 채널별
  • 병원 약국
  • 소매 약국
  • 드럭스토어
• 세계의 혈관 운동 증상 시장 : 최종 용도별
  • 병원 및 진료소
  • 전문센터
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2030년)

• 지역별 세계의 혈관 운동 증상 시장
• 북미의 혈관 운동 증상 시장
• 유럽의 혈관 운동 증상 시장
• 아시아태평양의 혈관 운동 증상 시장
• 기타 지역 혈관 운동 증상 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 치료법별 세계의 혈관 운동 증상 시장 성장 기회
  • 유통 채널별 세계의 혈관 운동 증상 시장 성장 기회
  • 최종 용도별 세계의 혈관 운동 증상 시장 성장 기회
  • 지역별 세계의 혈관 운동 증상 시장 성장 기회
• 세계 혈관 운동 증상 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 혈관 운동 증상 시장 능력 확대
  • 세계 혈관 운동 증상 시장의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 유력 기업 개요

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter and Gamble
• TherapeuticsMD
• Emcure Pharmaceuticals
• Eli Lily and Company
• Novartis
• Novo Nordisk
• Pfizer

영문목차

Vasomotor Symptoms Trends and Forecast

The future of the global vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets. The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

A more than 150-page report is developed to help in your business decisions.

Vasomotor Symptoms by Segment

The study includes a forecast for the global vasomotor symptoms by therapy type, distribution channel, end use, and region.

Vasomotor Symptoms Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

• Estrogen
• Progesterone
• Combination
• OTC Hormone
• Anti-Depressants
• Others

Vasomotor Symptoms Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

Vasomotor Symptoms Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals And Clinics
• Specialty Centers
• Others

Vasomotor Symptoms Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Vasomotor Symptoms Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies vasomotor symptoms companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the vasomotor symptoms companies profiled in this report include-

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter And Gamble
• Therapeuticsmd
• Emcure Pharmaceuticals
• Eli Lily And Company
• Novartis
• Novo Nordisk
• Pfizer

Vasomotor Symptoms Market Insights

Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Within this market, specialty centers will remain the larger segment due to more expertise in treating vasomotor symptoms.

North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Features of the Global Vasomotor Symptoms Market

Market Size Estimates: Vasomotor symptoms market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Vasomotor symptoms market size by therapy type, distribution channel, end use, and region in terms of value ($B).

Regional Analysis: Vasomotor symptoms market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy type, distribution channel, end use, and regions for the vasomotor symptoms market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the vasomotor symptoms market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for vasomotor symptoms market?

Answer: The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the vasomotor symptoms market?

Answer: The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

Q3. What are the major segments for vasomotor symptoms market?

Answer: The future of the vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets.

Q4. Who are the key vasomotor symptoms market companies?

Answer: Some of the key vasomotor symptoms companies are as follows.

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter And Gamble
• Therapeuticsmd
• Emcure Pharmaceuticals
• Eli Lily And Company
• Novartis
• Novo Nordisk
• Pfizer

Q5. Which vasomotor symptoms market segment will be the largest in future?

Answer: Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Q6. In vasomotor symptoms market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the vasomotor symptoms market by therapy type (estrogen, progesterone, combination, OTC hormone, anti-depressants, and others), distribution channel (hospital pharmacy, retail pharmacy, and drug stores), end use (hospitals and clinics, specialty centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Vasomotor Symptoms Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Vasomotor Symptoms Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Vasomotor Symptoms Market by Therapy Type
  • 3.3.1: Estrogen
  • 3.3.2: Progesterone
  • 3.3.3: Combination
  • 3.3.4: OTC Hormone
  • 3.3.5: Anti-Depressants
  • 3.3.6: Others
• 3.4: Global Vasomotor Symptoms Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Drug Stores
• 3.5: Global Vasomotor Symptoms Market by End Use
  • 3.5.1: Hospitals and Clinics
  • 3.5.2: Specialty Centers
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Vasomotor Symptoms Market by Region
• 4.2: North American Vasomotor Symptoms Market
  • 4.2.2: North American Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
• 4.3: European Vasomotor Symptoms Market
  • 4.3.1: European Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
  • 4.3.2: European Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
• 4.4: APAC Vasomotor Symptoms Market
  • 4.4.1: APAC Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
  • 4.4.2: APAC Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
• 4.5: ROW Vasomotor Symptoms Market
  • 4.5.1: ROW Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
  • 4.5.2: ROW Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Vasomotor Symptoms Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Vasomotor Symptoms Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Vasomotor Symptoms Market by End Use
  • 6.1.4: Growth Opportunities for the Global Vasomotor Symptoms Market by Region
• 6.2: Emerging Trends in the Global Vasomotor Symptoms Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Vasomotor Symptoms Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Vasomotor Symptoms Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Teva Pharmaceuticals
• 7.2: Merck
• 7.3: Mithra Pharmaceuticals
• 7.4: Procter and Gamble
• 7.5: TherapeuticsMD
• 7.6: Emcure Pharmaceuticals
• 7.7: Eli Lily and Company
• 7.8: Novartis
• 7.9: Novo Nordisk
• 7.10: Pfizer